Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 51,299

Document Document Title
WO/2017/042731A1
The present invention provides a process for the preparation of amorphous form of selexipag (Ia). The present invention also provides a novel amorphous form of selexipag sodium (Ib) and selexipag potassium (Ic) and methods for preparing ...  
WO/2017/041266A1
Provided is a wine for invigorating Qi and promoting blood circulation, which consists of: 20 grams of milk vetch root, 10 grams of doubleteeth pubescent angelica root, 10 grams of Divaricate Saposhnikovia root, 10 grams of prepared liqu...  
WO/2017/043563A1
The present invention relates to a method for producing a compound represented by formula (1) or a salt thereof, comprising a step of reacting a compound represented by formula (2) or a salt thereof with a compound represented by formula...  
WO/2017/042839A1
A eltrombopag tromethamine salt has been obtained and characterized. Pharmaceutical compositions comprising the elthrombopag tromethamine salt form can be used for treatment of diseases, including thrombocytopenia in patients with chroni...  
WO/2017/038860A1
The present invention is: a free polyunsaturated fatty acid-containing composition, which comprises at least one C20 or higher free polyunsaturated fatty acid, the content being at least 80.0% of the fatty acids in the composition, and s...  
WO/2017/037719A1
Novel aminoglycosides, represented by Formulae la and lb, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the s...  
WO/2017/037718A1
Novel pseudo-trisaccharide aminoglycosides, represented by Formula I, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions cont...  
WO/2017/037051A1
The invention relates to substituted oxopyridine derivatives and methods for the production thereof, as well as to the use thereof in the production of medicaments for treating and/or preventing diseases, especially diseases of the cardi...  
WO/2017/038861A1
Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is a...  
WO/2017/037717A1
Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are p...  
WO/2017/036255A1
The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.  
WO/2017/032276A1
Provided are bovine intestinal mucosa enoxaparin sodium, a preparation method therefor, and an application thereof. The bovine intestinal mucosa enoxaparin sodium is prepared from bovine intestinal mucosa heparin. Being different from en...  
WO/2017/033963A1
The present invention addresses the problem of providing a substance that has an effect of increasing ATP in cells, in particular, an ATP increasing agent that has an effect much stronger than the increasing effect achieved by using inos...  
WO/2017/032275A1
Provided are sheep enoxaparin sodium, a preparation method therefor, and an application thereof. The sheep enoxaparin sodium is prepared from sheep heparin. Compared with enoxaparin sodium that derives from porcine intestinal mucosa hepa...  
WO/2017/032277A1
Provided are a bovine lung enoxaparin sodium, a preparation method therefor, and an application thereof. The bovine lung enoxaparin sodium is prepared from bovine lung heparin, and the content of ΔUA2S-GlcNS6S(ΔⅠS) is up to 75% to ...  
WO/2017/033415A1
The purpose of the present invention is to provide a method for easily and efficiently promoting the expression of c-MPL on the surface of mesenchymal cells, etc. The method according to the present invention for producing mesenchymal ce...  
WO/2017/031051A1
The invention provides devices and methods for adjusting particle size in nanoemulsions of fluorocarbons and perfluorocarbons (e.g., perfluoropentane and perfluorohexane) via sonication (e.g., ultrasonication).  
WO/2017/027371A1
The disclosure provides polypeptides (e.g., mRNAs) capable of modulating expression of an ADAMTS13 protem, fragment, or variant that are useful for, among other things, cleaving vWF and, thus, treating diseases or disorders with unregula...  
WO/2017/024589A1
The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinas...  
WO/2017/024060A1
The present invention provides Factor IX (FIX) fusion proteins comprising at least one heterologous moiety, such as an XTEN. The present invention further discloses methods of making and using the FIX fusion proteins.  
WO/2017/020282A1
Provided is a multi-target compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism. The formula of the multi-target compound is as follows: A-L-B-L'-C. A and B are binding sites with a thrombin, C is a binding site with...  
WO/2017/022728A1
The present invention addresses the problem of providing: a novel peptide which can exert the medicinal effect or efficacy thereof rapidly and has a long duration of remission; and a medicine and an external preparation, particularly a p...  
WO/2017/022651A1
In the present invention, a composition comprising an antibody is adjusted to a state in which an anionic polymer is included at a pH below the antibody pI, and impurities that were insolubilized by the anionic polymer are removed. More ...  
WO/2017/023992A1
The present invention provides compounds of Formula (I): [INSERT CHEMICAL STRUCTURE HERE] (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are...  
WO/2017/023997A1
Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panxl hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.  
WO/2017/018473A1
The present invention provides a tablet in which the stability of active ingredients (a potassium ion-competitive acid blocker and acetylsalicylic acid) is high and the pharmacological activities of the active ingredients can be exerted ...  
WO/2017/018385A1
Provided are a method for assisting the diagnosis of conditions of myelofibrosis (MF), a method for assisting the prediction of prognosis of MF, and a method for monitoring a therapeutic effect on MF. Also provided is a device for perfor...  
WO/2017/019819A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or d...  
WO/2017/017187A1
There is provided a Colony Stimulating Factor (CSF) as an active ingredient for use in the treatment of colon or pancreatic cancerthrough an increase in neutrophilia, wherein the Colony Stimulating Factor is selected from the group consi...  
WO/2017/019828A1
Disclosed is a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein one R3 is H and the other R3 is an aryl group substituted with zero to 3 R3a; and R1, R2, and R3a a...  
WO/2017/019821A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or d...  
WO/2017/015619A1
In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In anotlier a...  
WO/2017/015619A8
In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another as...  
WO/2017/011913A1
The present disclosure provides compositions and methods for treating mucositis associated with treatment-induced neutropenia in a patient. The methods comprise applying a biophotonic composition comprising a fluorescent dye and a carrie...  
WO/2017/014315A1
Provided is an EP2 agonist having a high safety. A compound represented by general formula (I) (wherein each symbol is as defined in the description), a salt thereof, an N-oxide derivative thereof, a solvate of the same or a prodrug of t...  
WO/2017/013542A1
The object of the present invention is a product obtainable by spray-drying an aqueous solution comprising iron bis-glycinate chelate and alginic acid and/or water- soluble salts thereof, preferably sodium alginate, potassium alginate an...  
WO/2017/012289A1
Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said com...  
WO/2017/014170A1
Provided are: a heterocyclic compound which has an HDAC-inhibiting activity and is useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancer, central nervous system diseases including...  
WO/2017/011890A1
This invention relates to pharmaceutical compositions containing the peptide sequence of CxxC peptide designed based on the linear sequence of the dithiol active sites of PDI (protein disulfide isomerase) or structures derived therefrom,...  
WO2017010573A1
The invention provides lipid particles, etc., containing a double-stranded nucleic acid as a drug, and a cationic lipid represented by formula (A), etc., the double-stranded nucleic acid comprising a sense strand and an antisense strand ...  
WO/2017/010500A1
The purpose of the present invention is to provide a novel nucleic acid with which β2GPI expression can be inhibited and a pharmaceutical composition for the prevention or treatment of diseases associated with β2GPI expression. The for...  
WO/2017/010463A1
A novel domain in Aggrus which is involved in the binding to CLEC-2 was searched, and a monoclonal antibody capable of recognizing the domain was obtained. It is clearly found that a newly discovered PLAG4 domain is important for the bin...  
WO2017010575A1
Provided is a nucleic acid complex that comprises a sense chain and an antisense chain, and contains a ligand and a double-stranded nucleic acid containing a double-stranded region having at least 11 base pairs, wherein an oligonucleotid...  
WO/2017/004966A1
The present invention relates to a new pyrazine derivative, and preparation method and medical application thereof. The pyrazine derivative can remove a free radical, suppress calcium overload, has an effect of protecting cells, and is u...  
WO/2017/005786A1
The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.  
WO/2017/002840A1
Provided are: an endothelin receptor antagonist composition; a use of said composition as a substance for inhibiting the binding of endothelin to endothelin receptors; and a method for inhibiting the binding of endothelin receptor-bindin...  
WO/2017/004127A1
Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of Embigin to a recipient subject and can also optionally include ...  
WO/2016/206576A1
The present invention discloses deuterated thienopiperidine derivatives, a manufacturing method, and an application thereof. The deuterated thienopiperidine derivatives in the present invention are of the following formula (I). The prese...  
WO/2016/208642A1
A separation membrane for blood treatment, the membrane having: a separation membrane containing a polysulfone-based polymer and polyvinylpyrrolidone; and a coating film which is provided on at least a part of a surface of the separation...  
WO/2016/209809A1
The present invention relates to, inter alia, a novel crystalline free- plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L- arginine salt of (R)-2-(7...  

Matches 451 - 500 out of 51,299